Lexaria Bioscience - Lexaria Bioscience

NASDAQ:LEXX; NASDAQ WARRANT:LEXXW
  • Home
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Advisors & Consultants
  • Technology
    • Overview
    • Commercial Applications
    • Research
    • Patent Portfolio
  • Licensing Opportunities
  • Investors
Contact

Research Style 3

Lexaria Bioscience   →  Research Style 3

Research Style 3

Oncology

Nanostructured Materials

Pathology

Organic Synthesis

Biosafety, Incubator

Nuclear Micro-Reactors

Pathology

Laboratory Quality Control

Oncology

Cell And Molecular Biology

Incubator

Surface Cleaning

VACCINES

Polymer Science

Pathology

Catalysis Processes

Oncology

Translational Research

Pathology

Cancer Cell Biology

Biosafety

Metabolism Regulation

Incubator

DNA Vaccines

Lexaria Bioscience Corp. (NASDAQ:LEXX) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

250.765.6424
[email protected]

Canadian Operations
#100-740 McCurdy Road
Kelowna, BC, V1X2P7

US Operations
210 Shamrock Industrial Blvd., Suite C
Tyrone, GA 30290

Privacy Policy

General Disclaimer:
No statement in this web site has been evaluated by the Food and Drug Administration (FDA). Furthermore, none of the statements in this web site should be construed as dispensing medical advice or making claims regarding the cure of diseases…

Read More

Copyright © 2024 Lexaria Bioscience. All rights reserved.